ArticleBMC pulmonary medicine2019
Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia.
Article in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review.BMJ open respiratory research · 2020Pooled it
- Comparing Pneumonia Risks of Budesonide with Fluticasone Among Patients with Asthma in Hong Kong: A Territory-Wide Retrospective Study.Advances in therapy · 2026Article
- A study protocol for a randomised controlled trial of two stepwise pharmacological treatment approaches to adult asthma: inhaled corticosteroid/formoterol reliever-ERJ open research · 2026Article
- Determinants of pneumonia among adult asthmatic patients attending public hospitals in Awi Zone, Northwest Ethiopia: A case control study.SAGE open medicine · 2026Article
- Precision medicine for asthma treatment: Unlocking the potential of the epigenome and microbiome.The Journal of allergy and clinical immunology · 2025Review
- The Wiser Strategy of Using Beta-Agonists in Asthma: Mechanisms and Rationales.Allergy, asthma & immunology research · 2024Review
- Neutrophil to lymphocyte ratio in pediatric patients with asthmatic exacerbation and community-acquired pneumonia.BMC pediatrics · 2023Article
- Black Ginseng Extract Exerts Potentially Anti-Asthmatic Activity by Inhibiting the Protein Kinase Cθ-Mediated IL-4/STAT6 Signaling Pathway.International journal of molecular sciences · 2023Article
- Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma.Tuberculosis and respiratory diseases · 2023Article
- Asthma and Respiratory Infections From Birth to Young Adulthood.American journal of epidemiology · 2023Article
- The effects of asthma on the oxidative stress, inflammation, and endothelial dysfunction in children with pneumonia.BMC pediatrics · 2022Article
- Risk of pneumonia in asthmatic children using inhaled corticosteroids: a nested case-control study in a birth cohort.BMJ open · 2022Article
- House Dust Mite Aeroallergen Suppresses Leukocyte Phagocytosis and Netosis Initiated by Pneumococcal Lung Infection.Frontiers in pharmacology · 2022Article
- OM-85 Broncho-VaxomBiomedicines · 2021Article
- The risk of respiratory tract infections and antibiotic use in a general population and among people with asthma.ERJ open research · 2021Article
- Inhaled Corticosteroids Use and Risk of Invasive Pneumococcal Disease in a Population-based Study.Annals of the American Thoracic Society · 2020Article
- Inhaled Corticosteroids as an Associated Risk Factor for Asthmatic Pneumonia: A Literature Review.Cureus · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundPneumonia is an important cause of morbidity and mortality. COPD patients using inhaled corticosteroids (ICS) have an increased risk of pneumonia, but less is known about whether ICS treatment in asthma also increases the risk of pneumonia. The aim of this analysis was to examine risk factors for hospitalisations with pneumonia in a general population sample with special emphasis on asthma and the use of ICS in asthmatics.
methodsIn 1999 to 2000, 7340 subjects aged 28 to 54 years from three Swedish centres completed a brief health questionnaire. This was linked to information on hospitalisations with pneumonia from 2000 to 2010 and treatment with ICS from 2005 to 2010 held within the Swedish National Patient Register and the Swedish Prescribed Drug Register.
resultsParticipants with asthma (n = 587) were more likely to be hospitalised with pneumonia than participants without asthma (Hazard Ratio (HR 3.35 (1.97-5.02)). Other risk factors for pneumonia were smoking (HR 1.93 (1.22-3.06)), BMI < 20 kg/m2 (HR 2.74 (1.41-5.36)) or BMI > 30 kg/m2 (HR 2.54 (1.39-4.67)). Asthmatics (n = 586) taking continuous treatment with fluticasone propionate were at an increased risk of being hospitalized with pneumonia (incidence risk ratio (IRR) 7.92 (2.32-27.0) compared to asthmatics that had not used fluticasone propionate, whereas no significant association was found with the use of budesonide (IRR 1.23 (0.36-4.20)).
conclusionHaving asthma is associated with a three times higher risk of being hospitalised for pneumonia. This analysis also indicates that there are intraclass differences between ICS compounds with respect to pneumonia risk, with an increased risk of pneumonia related to fluticasone propionate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.